Exercise and Compression for Lymphedema

Breast Cancer Related Lymphedema Clinical Trial

— DREAM  

Official title:

Decongestive Progressive Resistance Exercise With Advanced Compression for Breast Cancer Related Lymphedema Management (DREAM): A Randomized Control Trial

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05022823
• Other study ID #: IIT-0016
• Status: Active, not recruiting
• Phase: N/A
• Start date: June 29, 2022
• Est. completion date: May 31, 2024

Study information

• Verified date: September 2023
• Source: AHS Cancer Control Alberta
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to investigate the benefit of combining resistance exercise with use of a compression sleeve on arm lymphedema. In the study, participants will be taught a resistance exercise that follows the decongestive exercise sequence. This program is called "decongestive progressive resistance exercise" (DPRE). To evaluate the benefit from use of a compression garment on the arm. Some participants will wear their usual compression sleeve during exercise and others will use an adjustable compression wrap. The investigators hope to see if this type of combined program is helpful for women with lymphedema. The investigators also want to see if there are benefits from the addition of use of an adjustable compression wrap during exercise over use of a regularly prescribed compression sleeve.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 40
• Est. completion date: May 31, 2024
• Est. primary completion date: May 31, 2024
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Is a female with a history of breast cancer;

2. Has undergone surgery, including sentinel lymph node biopsy or axillary lymph node dissection;

3. Has visible and palpable unilateral mild to moderate BCRL of at least 200 ml inter-limb volume difference (full limb) or regional lymphedema: defined as a minimal volume difference of 100 ml or 5% in a segment of the arm (e.g. hand and forearm region, elbow and upper arm) after correcting for arm dominance;

4. Has chronic lymphedema, defined as lymphedema that has been present for at least 3 months;

5. Is in the lymphedema maintenance phase of conservative treatment;

6. Uses a well fitted compression sleeve (not older than 1 month) and is agreeable to wear the sleeve for a minimum of 12 hours per day (providing a minimum of 30 mm Hg of pressure);

7. Is agreeable to discontinuing other lymphedema treatments that are beyond standard care, including manual lymph drainage and intermittent pneumatic compression during the 12-week RCT period of the study.

8. Is able to read and understand English.

Exclusion Criteria:

1. Are undergoing or are scheduled to receive chemotherapy or radiotherapy

2. Presents with limb infection/ cellulitis, deep vein thrombosis, or have active metastatic disease;

3. Has any neurological or cognitive deficit, is pregnant, uses a pacemaker, or has other uncontrolled health condition that may interfere with assessment and/or the progressive resistance exercise training intervention;

4. Has any contraindications related to wearing compression on the limb, including arterial insufficiency or congestive heart failure;

Related Conditions & MeSH terms

• Breast Cancer Lymphedema
• Breast Cancer Related Lymphedema
• Breast Neoplasms
• Lymphedema

Intervention

Device:
• Compression sleeve, worn during exercise
Participants wear their daytime compression sleeve during the DPRE program.
• Adjustable Compression (AC) garment, worn during exercise
Participants wear an Adjustable Compression (AC) garment during the DPRE program. Participants will be fitted for an Adjustable Compression garment and instructed in its application by a physical therapist.
• Compression sleeve, daytime wear
Compression sleeve worn for at least 12 hours per day, seven days a week.

Behavioral:
• Decongestive Progressive Resistance Exercise program
Supervised DPRE exercise program, twice a week for 12 weeks. Exercises will be individualized and offered in a group-based format. After the 12-week intervention, participants will continue the same program (independently) twice weekly for an additional 12 weeks at home or in a community-based fitness center or attend supervised group exercise sessions virtually.
• Home exercise program
Participants are provided with a home exercise program that follows the decongestive exercise sequence and instructed to perform the exercise sequence once daily for a 10-15 minute period.

Locations

Country	Name	City	State
Canada	Cross Cancer Institute	Edmonton	Alberta

Sponsors (1)

Lead Sponsor	Collaborator
AHS Cancer Control Alberta

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Lymphedema Arm Volume	Lymphedema will be objectively measured using the optoelectronic limb volumeter (perometer).	Up to 24 weeks
Secondary	Change in Extracellular Fluid Volume	Bioimpedance analysis (BIA) is specially designed to estimate extracellular fluid volume in the limb. BIA measures the impedance ratio of the affected and unaffected limb and the resulting calculated index provides an estimate of extracellular fluid volume.	Up to 24 weeks
Secondary	Change in Muscle Strength	Muscle strength will be assessed with the one-repetition maximum (1-RM) method for bench press, leg press, and seated row. The 1-RM is the highest weight that can be lifted once using proper form, a smooth motion and without pain or other symptoms.	Up to 24 weeks
Secondary	Change in Grip Strength	The Jamar hydraulic hand dynamometer will be used to measure grip strength.	Up to 24 weeks
Secondary	Change in Shoulder Range of Motion	Shoulder range of motion (ROM) will be measured using plastic goniometer and each arm will be measured separately for flexion, abduction, internal, external rotation, and horizontal abduction.	Up to 24 weeks
Secondary	Health-Related Quality of Life (Lymph-ICF)	The Lymphedema Functioning, Disability, and Health (Lymph-ICF) questionnaire consists of 29 questions related to functional impairments, activity limitations, and participation restrictions in patients with upper limb lymphedema.The total score of the Lymph-ICF on the five areas ranges from 0 to 100, with a score of 0 meaning no impact and higher scores indicative of worse function or negative impact.	Up to 24 weeks
Secondary	Health-Related Quality of Life (SF-36)	The Rand Short Form-36 Version 2 (SF-36) questionnaire is comprised of 36 questions that aim to evaluate the following eight models of HRQOL: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality/energy, social functioning, role limitations due to emotional problems, and general mental health.	Up to 24 weeks
Secondary	Physical Activity Level	The Godin leisure-time exercise questionnaire (GLTEQ) will be used to assess the physical activity level. The Godin questionnaire is a self reported measure of the average duration and frequency of strenuous (heart beats rapidly), moderate (not exhausting), and mild activities (minimal effort), resistance training, and flexibility training exercise.	Up to 24 weeks
Secondary	Exercise and Compression Adherence	Participants will be asked to record their adherence to their assigned exercise and compression intervention program using a daily diary.The adherence diary will collect details on exercise sessions performed each day, including sets, repetitions, and resistance weight, as well as use of the assigned compression sleeve (i.e. use of the garment during exercises and number of hours per day and days per week the compression sleeve is worn).	Up to 24 weeks

External Links

•   Link to the pilot study